CASI Pharma (CASI) Partner, BioInvent International AB, Report Phase I/IIA Data that Suggests BI-1206 Restores Activity Of Rituximab in Relapsed Non-Hodgkin's Lymphoma Patients
Go back to CASI Pharma (CASI) Partner, BioInvent International AB, Report Phase I/IIA Data that Suggests BI-1206 Restores Activity Of Rituximab in Relapsed Non-Hodgkin's Lymphoma Patients| Careside, Inc. (NASDAQ: CASI) | Delayed: 2.41 -0.03 (1.23%) | |||||
|---|---|---|---|---|---|---|
| Previous Close | $2.44 | 52 Week High | $1.70 | |||
| Open | $2.49 | 52 Week Low | $0.58 | |||
| Day High | $2.61 | P/E | N/A | |||
| Day Low | $2.22 | EPS | $0.00 | |||
| Volume | 18,144 | |||||
